11.30

1.21% 0.145

Dynavax Technologies Corp (DVAX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Dynavax Technologies Corp stock is traded at $11.30, with a volume of 287.61K. It is up +1.21% in the last 24 hours and up +14.55% over the past month. Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Previous Close:

$11.16

Open:

$11.17

24h Volume:

287.61K

Relative Volume:

0.15

Market Cap:

$1.36B

Revenue:

$260.81M

Net Income/Loss:

$20.48M

P/E Ratio:

86.96

EPS:

0.13

Net Cash Flow:

$22.67M

1W Performance:

+5.36%

1M Performance:

+14.55%

6M Performance:

-11.34%

1Y Performance:

-1.61%

1-Day Range:

$11.07

$11.31

1-Week Range:

$10.74

$11.48

52-Week Range:

$9.22

$14.63

Dynavax Technologies Corp Stock (DVAX) Company Profile

Name

Dynavax Technologies Corp

Sector

Healthcare (1162)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

(510) 848-5100

Address

2100 POWELL STREET, EMERYVILLE, CA

Employee

405

Twitter

@DynavaxCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

DVAX's Discussions on Twitter

Compare DVAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DVAX Dynavax Technologies Corp	11.31	1.36B	260.81M	20.48M	22.67M	0.13
ZTS Zoetis Inc	151.94	68.32B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.44	46.55B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.815	43.80B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.39	19.01B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	305.23	13.79B	2.99B	1.21B	1.13B	25.06

Dynavax Technologies Corp Stock (DVAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-11-25	Downgrade	Goldman	Neutral → Sell
Feb-01-24	Initiated	Goldman	Neutral
Sep-27-22	Initiated	JMP Securities	Mkt Outperform
Jan-06-22	Resumed	Goldman	Buy
Aug-06-21	Initiated	Goldman	Buy
Aug-07-20	Reiterated	H.C. Wainwright	Buy
Aug-03-20	Reiterated	H.C. Wainwright	Buy
Jun-15-20	Initiated	Evercore ISI	Outperform
Oct-18-19	Initiated	H.C. Wainwright	Buy
Jul-11-19	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-27-19	Reiterated	Cantor Fitzgerald	Overweight
May-10-18	Upgrade	JP Morgan	Neutral → Overweight
Mar-08-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-14-18	Downgrade	JP Morgan	Overweight → Neutral
Sep-25-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	Cantor Fitzgerald	Overweight
Jul-31-17	Upgrade	JP Morgan	Neutral → Overweight
Jul-31-17	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-09-17	Reiterated	RBC Capital Mkts	Sector Perform
Apr-28-16	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-27-16	Downgrade	JP Morgan	Overweight → Neutral
Nov-30-15	Initiated	RBC Capital Mkts	Outperform
Nov-25-13	Upgrade	MLV & Co	Hold → Buy
Feb-25-13	Downgrade	MLV & Co	Buy → Hold
Nov-16-12	Reiterated	MLV & Co	Buy

View All

Dynavax Technologies Corp Stock (DVAX) Latest News

06:18 AM

What drives Dynavax Technologies Corporation stock priceFree Stock Market Query - Autocar Professional

06:18 AM

Jul 24, 2025

How high can Dynavax Technologies Corporation stock price go in 2025Strongest growth potential - jammulinksnews.com

Jul 24, 2025

Jul 22, 2025

Why Dynavax Technologies Corporation stock attracts strong analyst attentionTop Performing Stocks - Newser

Jul 22, 2025

Jul 21, 2025

Bank of New York Mellon Corp Has $11.56 Million Position in Dynavax Technologies Corporation (NASDAQ:DVAX) - Defense World

Jul 21, 2025

Jul 19, 2025

Dynavax Technologies Corporation Stock Analysis and ForecastMarket-leading growth rates - jammulinksnews.com

Jul 19, 2025

Jul 17, 2025

what makes dynavax technologies corporation stock price move sharplyFree Stock Market Insider Analysis - Newser

Jul 17, 2025

US FDA approves pre-filled version of GSK's shingles vaccine - Reuters

Jul 17, 2025

Jul 16, 2025

Principal Financial Group Inc. Purchases 19,830 Shares of Pitney Bowes Inc. (NYSE:PBI) - Defense World

Jul 16, 2025

Principal Financial Group Inc. Has $7.92 Million Stake in Dynavax Technologies Corporation (NASDAQ:DVAX) - Defense World

Jul 16, 2025

Jul 15, 2025

What makes Dynavax Technologies Corporation stock price move sharplyReal Chart Play - Newser

Jul 15, 2025

How Dynavax Technologies Corporation stock performs during market volatilityFree Stock Index Interpretation - Newser

Jul 15, 2025

Jul 13, 2025

Cambridge Investment Research Advisors Inc. Makes New $312,000 Investment in Dynavax Technologies Corporation (NASDAQ:DVAX) - Defense World

Jul 13, 2025

Jul 06, 2025

Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31 - Insider Monkey

Jul 06, 2025

Jul 05, 2025

13 Best Pharma Stocks to Buy According to Wall Street Analysts - Insider Monkey

Jul 05, 2025

Jun 28, 2025

State of Alaska Department of Revenue Has $878,000 Stock Position in Dynavax Technologies Corporation (NASDAQ:DVAX) - Defense World

Jun 28, 2025

Jun 25, 2025

Is Dynavax Technologies Corp. overvalued or undervalued? - MarketsMojo

Jun 25, 2025

Jun 24, 2025

Dynavax’s SWOT analysis: heplisav-b maker’s stock rises on strong sales - Investing.com Canada

Jun 24, 2025

Jun 23, 2025

Pharma & Vaccine Industry Leader Eddie Gray joins Botanical Solution Inc. (BSI) Board of Directors - Business Wire

Jun 23, 2025

Jun 18, 2025